Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH. / Kjaer, Anna Sophie L; Jensen, Rikke Beck; Petersen, Jørgen H; Linneberg, Allan; Kårhus, Line Lund; Henriksen, Louise Scheutz; Johannsen, Trine Holm; Main, Katharina M; Hoffman, Andrew R; Juul, Anders.
I: The Journal of clinical endocrinology and metabolism, Bind 108, Nr. 3, 2023, s. 642–652.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Tracking and Cumulative Lifetime Exposure to IGF-I in 6,459 Healthy Individuals and in SGA Children Treated with GH
AU - Kjaer, Anna Sophie L
AU - Jensen, Rikke Beck
AU - Petersen, Jørgen H
AU - Linneberg, Allan
AU - Kårhus, Line Lund
AU - Henriksen, Louise Scheutz
AU - Johannsen, Trine Holm
AU - Main, Katharina M
AU - Hoffman, Andrew R
AU - Juul, Anders
N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2023
Y1 - 2023
N2 - CONTEXT: Supraphysiological serum insulin-like growth-factor-I (IGF-I) concentrations have been a matter of concern in children treated with growth hormone (GH) because high IGF-I levels were associated with risk of later disease in former epidemiological studies.OBJECTIVE: To determine whether a single IGF-I measurement reliably reflects lifetime IGF-I exposure we evaluated intraindividual longitudinal tracking of IGF-I and IGF-binding-protein-3 (IGFBP-3) levels and we estimated cumulative lifetime exposure to IGF-I in healthy and GH-treated individuals.METHODS: We included 6,459 healthy participants (cross-sectional = 5,326; longitudinal = 1,133) aged 0----76 years (9,963 serum samples) and nine patients born small-for-gestational-age (SGA) with 238 serum samples during GH treatment.Intraindividual tracking of IGF-I and IGFBP-3 (SDS) was determined by intraclass correlation coefficients (ICC). Cumulative lifetime IGF-I exposure was estimated by area under the curve of the predicted SDS-trajectory from 0-76 years.RESULTS: For IGF-I (SDS), ICCs were 0.50 (95% CI: 0.47-0.53) for male and 0.53 (0.50-0.56) for female participants. Lifetime IGF-I exposure was significantly higher in female (mean 12,723 ± 3,691 SD) than in male participants (12,563 ± 3,393); p = 0.02. In SGA children, treatment with GH increased the lifetime exposure to IGF-I from 9,512 ± 1,889 to 11,271 ± 1,689, corresponding to an increase in lifetime IGF-I trajectory from -0.89 SD ± 0.57 to -0.35 SD ± 0.49.CONCLUSION: Since IGF-I and IGFBP-3 levels track throughout life, a single measurement reliably reflects lifetime exposure. GH therapy increased the lifetime exposure to IGF-I only slightly and it remained below the average lifetime exposure in the reference population.
AB - CONTEXT: Supraphysiological serum insulin-like growth-factor-I (IGF-I) concentrations have been a matter of concern in children treated with growth hormone (GH) because high IGF-I levels were associated with risk of later disease in former epidemiological studies.OBJECTIVE: To determine whether a single IGF-I measurement reliably reflects lifetime IGF-I exposure we evaluated intraindividual longitudinal tracking of IGF-I and IGF-binding-protein-3 (IGFBP-3) levels and we estimated cumulative lifetime exposure to IGF-I in healthy and GH-treated individuals.METHODS: We included 6,459 healthy participants (cross-sectional = 5,326; longitudinal = 1,133) aged 0----76 years (9,963 serum samples) and nine patients born small-for-gestational-age (SGA) with 238 serum samples during GH treatment.Intraindividual tracking of IGF-I and IGFBP-3 (SDS) was determined by intraclass correlation coefficients (ICC). Cumulative lifetime IGF-I exposure was estimated by area under the curve of the predicted SDS-trajectory from 0-76 years.RESULTS: For IGF-I (SDS), ICCs were 0.50 (95% CI: 0.47-0.53) for male and 0.53 (0.50-0.56) for female participants. Lifetime IGF-I exposure was significantly higher in female (mean 12,723 ± 3,691 SD) than in male participants (12,563 ± 3,393); p = 0.02. In SGA children, treatment with GH increased the lifetime exposure to IGF-I from 9,512 ± 1,889 to 11,271 ± 1,689, corresponding to an increase in lifetime IGF-I trajectory from -0.89 SD ± 0.57 to -0.35 SD ± 0.49.CONCLUSION: Since IGF-I and IGFBP-3 levels track throughout life, a single measurement reliably reflects lifetime exposure. GH therapy increased the lifetime exposure to IGF-I only slightly and it remained below the average lifetime exposure in the reference population.
U2 - 10.1210/clinem/dgac605
DO - 10.1210/clinem/dgac605
M3 - Journal article
C2 - 36250350
VL - 108
SP - 642
EP - 652
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 3
ER -
ID: 331771912